Phase I/II Trial Evaluating Five Fraction SABR Dose Escalation for Early Stage Squamous Cell Carcinoma of the Lung

T
Tim Lautenschlaeger, MD

Primary Investigator

Overview

The purpose of this study is to test whether 5 fraction stereotactic ablative body radiation (SABR) is safe and improves local control for early state squamous cell carcinoma of the lung.

Description

The purpose of this study is to evaluate the amount of radiation used in stereotactic ablative ratiotherapy (SABR). This study asks if patients with non-small cell lung cancer of the lung squamous cell subtype can safely receive more radiation. If a higher radiation dose is found to be safe, the study then asks if that higher dose can control the cancer better than the current standard dose.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    lung cancer,squamous cell carcinoma of the lung
  • Age: Between 18 Years - 100 Years
  • Gender: All

Inclusion Criteria
Pathological diagnosis of squamous cell carcinoma of the lung
Exclusion Criteria
Previous radiation therapy to the lung per investigator discretion


Additional Information:
Participants will not be paid for their participation.

Updated on 20 Nov 2022. Study ID: 1706985235 (IUSCC-0624)

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center